MABD51
Anti-Brn-2 (POU3F2) Antibody, clone 8C4.2
clone 8C4.2, from mouse
別名:
POU domain, class 3, transcription factor 2, Brain-specific homeobox/POU domain protein 2, Brain-2, Brn-2, Nervous system-specific octamer-binding transcription factor N-Oct-3, Octamer-binding protein 7, Oct-7, Octamer-binding transcription factor 7, OTF
ログイン組織・契約価格を表示する
すべての画像(3)
About This Item
UNSPSCコード:
12352203
eCl@ss:
32160702
NACRES:
NA.41
おすすめの製品
由来生物
mouse
品質水準
抗体製品の状態
purified immunoglobulin
抗体製品タイプ
primary antibodies
クローン
8C4.2, monoclonal
交差性
rat, human
テクニック
immunohistochemistry: suitable (paraffin)
western blot: suitable
アイソタイプ
IgG1κ
NCBIアクセッション番号
UniProtアクセッション番号
輸送温度
wet ice
ターゲットの翻訳後修飾
unmodified
遺伝子情報
human ... POU3F2(5454)
詳細
Brn-2 (POU domain, class 3, transcription factor 2; Oct-7; N-Oct-3; or POU3F2) is a member of a large family of POU-domain transcription factors. The highly homologous POU domain contains a POU-specific domain at the N-terminus, a POU-homeo domain at the C-terminus and an interconnecting linker region. The POU domain binds to the DNA sequence 5’-ATGCAAAT-3’. Brn-2 is highly expressed in the developing CNS and may play a role in neurogenesis, particularly in the development of the hypothalamus. Previous studies have also suggested that Brn-2 integrates signals downstream of the BRAF/MAP kinase and Wnt/β-catenin pathways, and Brn-2 may be involved in the transformation and proliferation of melanomas.
免疫原
GST-tagged recombinant protein corresponding human Brn-2 (POU3F2).
アプリケーション
Anti-Brn-2 (POU3F2) Antibody, clone 8C4.2 detects level of Brn-2 (POU3F2) & has been published & validated for use in Western Blotting, IHC(P).
Immunohistochemistry Analysis: A 1:50 dilution from a representative lot detected Brn-2 in normal rat brain tissue, in Purkinje, basket, and glial cells of rat cerebellum tissue, in neurons of rat cerebellum tissue, in neurons and glial cells of rat frontal cortex tissue, and in neurons of human pons tissue.
品質
Evaluated by Western Blot in SK-N-MC cell lysates.
Western Blot Analysis: A 1:2,000 dilution of this antibody detected Brn-2 (POU3F2) in 10 µg of SK-N-MC cell lysates.
Western Blot Analysis: A 1:2,000 dilution of this antibody detected Brn-2 (POU3F2) in 10 µg of SK-N-MC cell lysates.
ターゲットの説明
~54 kDa observed.
The calculated molecular weight is 47 kDa Brn-2 (POU3F2) may be observed at ~50-55 kDa in some cell lysates (Wolfe, A., et al., (2002). Molecular Endocrinology. 16(3):435-449).
The calculated molecular weight is 47 kDa Brn-2 (POU3F2) may be observed at ~50-55 kDa in some cell lysates (Wolfe, A., et al., (2002). Molecular Endocrinology. 16(3):435-449).
物理的形状
Format: Purified
アナリシスノート
Control
SK-N-MC cell lysates
SK-N-MC cell lysates
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
保管分類コード
12 - Non Combustible Liquids
WGK
WGK 1
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
MABD51:
試験成績書（COA）
製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Meitetsu Masawa et al.
The American journal of pathology, 192(6), 847-861 (2022-04-04)
Although recent reports have revealed the importance of the inactivation of both RB1 and TP53 in the transformation from lung adenocarcinoma into neuroendocrine carcinoma (NEC), the requirements for complete transformation into NEC have not been elucidated. To investigate alterations in
Zhongyuan Bao et al.
Oxidative medicine and cellular longevity, 2021, 6338722-6338722 (2021-12-03)
Traumatic brain injury (TBI) causes a high rate of mortality and disability, and its treatment is still limited. Loss of neurons in damaged area is hardly rescued by relative molecular therapies. Based on its disease characteristics, we transplanted human embryonic
Yilin Feng et al.
STAR protocols, 4(3), 102346-102346 (2023-07-08)
In glioma modeling, existing organoid protocols lack the ability to replicate glioma cell invasion and interaction with normal brain tissue. Here, we present a protocol for generating in vitro brain disease models using human-induced pluripotent- or embryonic-stem-cell-derived cerebral organoids (COs). We
Waseem K Raja et al.
PloS one, 17(12), e0277532-e0277532 (2022-12-02)
There are currently no preventive or disease-modifying therapies for Parkinson's Disease (PD). Failures in clinical trials necessitate a re-evaluation of existing pre-clinical models in order to adopt systems that better recapitulate underlying disease mechanisms and better predict clinical outcomes. In
Aaron Gordon et al.
Nature neuroscience, 24(3), 331-342 (2021-02-24)
Human stem-cell-derived models provide the promise of accelerating our understanding of brain disorders, but not knowing whether they possess the ability to mature beyond mid- to late-fetal stages potentially limits their utility. We leveraged a directed differentiation protocol to comprehensively
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）